Treatment with TGF-β R1 kinase inhibitor (R1-Ki) in mouse mammary tumor cells reduced tumor volume in the bone microenvironment via TGF-β activation of ERK 1/2 and Akt pathways, but BMP signaling did not contribute to tumor growth (Futakuchi et al., 2019). The gene discussed is TGFB1; the disease is breast cancer.